Oncology — Sep 21 – Sep 25, 2026 (Wk 39): Oncology Week: J&J Myeloma Data, Moderna’s Upcoming ESMO Test, and Pipeline Focus

September 25, 2026 · · 8 min read
Weekly theme roundup · Sep 21 – Sep 25, 2026
Covering the 63 Oncology stocks in our database — browse every Oncology name →

TL;DR — This week in oncology saw significant clinical trial data from Johnson & Johnson impacting long-term survival expectations in myeloma. Moderna's stock reacted to upcoming data presentations at ESMO, highlighting the importance of clinical milestones. Several companies, including IDEAYA Biosciences and Cullinan Therapeutics, were in focus due to their pipelines and strategic positioning in the oncology space.

Median price / model value
1.00×
the typical stock trades above our model value · 63 stocks
Insider tape (CMP-filtered)
0 buys
open-market, routine & 10b5-1 stripped

What moved

  • Johnson & Johnson's Phase 3 myeloma data was released, which has led to a re-evaluation of long-term survival expectations in the treatment of this cancer. This kind of data is crucial as it directly impacts the perceived efficacy and market potential of a drug, potentially shifting treatment paradigms and competitive landscapes within the myeloma segment. (src: [1]) [simplywall.st]
  • Moderna's stock experienced a 7% jump, with attention now turning to its upcoming presentation at the European Society for Medical Oncology (ESMO) on October 24. Clinical conference presentations, especially from major events like ESMO, are significant catalysts for biotech stocks as they provide updates on drug development, which can validate or challenge a company's pipeline value. (src: [3]) [TIKR.com]
  • IDEAYA Biosciences was highlighted for its efforts in navigating uncharted oncology territory, suggesting a focus on novel therapeutic approaches. Success in developing first-in-class or best-in-class therapies in new areas can lead to significant market opportunities and competitive advantages, though it also carries higher development risk. (src: [0]) [Insider Monkey]
  • Relay Therapeutics began a Phase 3 trial, a critical step in drug development that, if successful, can lead to regulatory approval and commercialization. The initiation of late-stage trials signals progress in a company's pipeline and can influence investor perception of its future revenue potential. (src: [12]) [simplywall.st]
  • Goldman Sachs initiated coverage on Revolution stock with a 'buy' rating, citing its oncology platform. Analyst ratings and coverage can draw attention to a company and its underlying technology, potentially influencing market sentiment and valuation, particularly for companies with promising but early-stage platforms. (src: [11]) [Investing.com Canada]

The why behind the week

  • The week's activity underscores the critical role of clinical trial data and pipeline development in the oncology sector. Positive Phase 3 data, as seen with Johnson & Johnson, can redefine treatment expectations and market share, while upcoming presentations, like Moderna's at ESMO, are key milestones that can validate a company's scientific approach and future commercial prospects. The focus on 'uncharted territory' by companies like IDEAYA Bio [Insider Monkey] [simplywall.st] [TIKR.com] [simplywall.st] [simplywall.st]
  • Strategic portfolio management and pipeline strength remain central themes, with discussions around AbbVie's efforts to rebuild its oncology portfolio beyond Imbruvica and comparisons between major pharma companies like AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb. For large pharmaceutical companies, a robust and diversified oncology pipeline is essential for long-term growth and mitigating risks associated with patent expirations or clini [The Globe and Mail] [The Globe and Mail] [The Globe and Mail] [The Globe and Mail] [The Globe and Mail]
  • Market sentiment and analyst coverage also played a role, with Goldman Sachs initiating coverage on Revolution stock and KURA ONCOLOGY filing a Form 144. These actions can reflect growing interest in specific companies or technologies within the oncology space, potentially influencing liquidity and market visibility. (src: [2, 11]) [Investing.com Canada] [Investing.com Canada]

📄 Filings that matter (8-Ks, straight from EDGAR)

  • $HURA — took on a new debt obligation [SEC filing] 2026-09-24
  • $SNTI — officer/director departure or appointment [SEC filing] 2026-09-24
  • $HCWB — entered a material agreement; unregistered equity sale [SEC filing] 2026-09-24
  • $JAZZ — entered a material agreement; took on a new debt obligation [SEC filing] 2026-09-23
  • $ZYME — entered a material agreement; completed an acquisition or disposition; took on a new debt obligation [SEC filing] 2026-09-23
  • $CORT — officer/director departure or appointment [SEC filing] 2026-09-23
  • $HALO — entered a material agreement; took on a new debt obligation; unregistered equity sale [SEC filing] 2026-09-22
  • $TCRT — entered a material agreement [SEC filing] 2026-09-22

The macro backdrop

10-yr Treasury 5.11%Expected inflation 2.3%VIX 15.5High-yield spread 2.80%Yield curve (10y–2y) 0.31%Chance of a 10%+ market fall in 3 months 8% (normal 14%)
How to read it
  • Credit Spread: tight — credit markets are relaxed, no stress being priced
  • Yield Curve: flat — the recession-warning zone; a rapid steepening from here has often preceded the actual downturn
  • Vix: calm — the market is complacent, which cuts both ways (little cushion if news turns)

Every theme swims in this tide — judge the week’s moves against it.

📅 On the calendar — and why it matters here

  • Fri Sep 25 — FOMC (Fed rate decision / minutes). the single biggest scheduled market mover — a rate surprise in either direction repriced everything, hardest on rate-sensitive names (growth, REITs, utilities, homebuilders). Watch for a surprise vs expectations — that gap, not the number itself, is what moves markets.
  • Tue Sep 29 — JOLTS (job openings). labor-market tightness — a cooling read eases wage-inflation fears. Watch for a surprise vs expectations — that gap, not the number itself, is what moves markets.
  • Wed Sep 30 — GDP. the broadest growth read — confirms or breaks the soft-landing thesis. Watch for a surprise vs expectations — that gap, not the number itself, is what moves markets.
  • Wed Sep 30 — PCE inflation (the Fed's gauge). a hot print pushes rate-cut odds out (pressuring long-duration assets); a soft print does the reverse — one of the highest-impact releases. Watch for a surprise vs expectations — that gap, not the number itself, is what moves markets.
  • Fri Oct 2 — Jobs report (payrolls + unemployment). sets the growth-vs-recession narrative — a weak number lifts recession odds (hits cyclicals, consumer, financials); a strong one can paradoxically pressure rates. Watch for a surprise vs expectations — that gap, not the number itself, is what moves markets.

What to watch next

  • The upcoming ESMO conference on October 24 will be a key event, particularly for Moderna, as clinical data presentations can significantly impact perceptions of a company's drug candidates and its competitive position. These events often serve as inflection points for drug developers, with positive data potentially increasing confidence in future regulatory approvals and commercial success. (src: [3, 14]) [TIKR.com] [simplywall.st]
  • The broader economic environment, characterized by a 10-year Treasury yield of 5.11% and a high-yield credit spread of 2.8%, indicates a higher cost of capital. For oncology companies, particularly those in early development stages, access to affordable financing is crucial for funding research, clinical trials, and potential commercialization efforts. Higher financing costs can impact the viability of projects and the overall valuation of growth [macro data]
  • The VIX at 15.49 suggests moderate market volatility. While not extremely high, this level indicates some investor caution. In the oncology sector, which often involves significant R&D risk and long development timelines, moderate volatility can lead to more discerning capital allocation and a greater emphasis on companies with strong clinical data and clear paths to market. (src: ["macro"]) [macro data]
  • The Shiller CAPE ratio of 41.25 suggests a generally high valuation across the broader market. For oncology stocks, this could imply that investors are already pricing in significant future growth, meaning that any clinical setbacks or delays could lead to notable share price adjustments. (src: ["macro"]) [macro data]

This week’s headlines (sources)

Every claim above cites its source — headlines link to the original outlet; [SAVNG data] marks our own EDGAR-computed figures. Where our sources don’t explain a move, we say so rather than guess. All weekly roundups →

All Oncology roundups: 2026-W41 · 2026-W40 · 2026-W38 · 2026-W37 · 2026-W36 · every scope →

SAVNG is an educational research publication, not a Registered Investment Adviser. Everything here is general-circulation information produced by an automated pipeline — the same for every reader — and is not personalized investment advice, an offer, or a recommendation to buy or sell any security. Any performance figure is hypothetical; past performance does not predict future results. Details.

Get next week's roundup automatically

Get these in any reader — no email, no account. Paste a link into Feedly, Inoreader, NetNewsWire, or your browser.